AB&B BIO-TECH-B (02627) surged over 8%. As of press time, the stock was up 7.49% to HK$51.25 with a turnover of HK$18.463 million.

On the news front, AB&B BIO-TECH-B recently announced that the company's board of directors is pleased to announce that China's National Medical Products Administration (NMPA) has approved the group's new drug application for a quadrivalent influenza virus subunit vaccine targeting the 6-35 month age group. This vaccine has become China's first and only approved full-population, full-dose quadrivalent influenza virus subunit vaccine for market launch.

The product represents a major upgrade from traditional virus split vaccines, offering advantages including comprehensive protection, high antigen purity, and low risk of adverse reactions. As a Class I new drug for preventive biological products in China, the quadrivalent influenza virus subunit vaccine entered the commercial insurance innovative drug catalog preliminary review list in August this year, and is the only vaccine product selected for the list, demonstrating significant scarcity. It is expected to effectively fill the corresponding market gap after launch.

Currently, the mainstream products in the domestic market are second-generation ordinary split influenza vaccines, while AB&B BIO-TECH-B's developed "subunit" influenza vaccine belongs to the third-generation technology route. Building upon split vaccines, it further optimizes production processes by extracting only the effective antigen components from the virus surface - hemagglutinin (HA) and neuraminidase (NA) - significantly improving antigen purity and reducing impurity content, providing clear advantages in safety, immune efficacy, and overall quality.